During 2014’s third quarter, device firms raised a total of $734 million, less than half of Q2’s $1.6 billion. (See Exhibit 1.) The deal activity was pretty evenly spread out among financing vehicles, with the exception of follow-on public offerings, which accounted for a mere 6% of the total with just one $6 million deal by biomaterials company Xtant Medical Holdings Inc.[See Deal]
Device/Diagnostics Quarterly Deal Statistics, Q3 2014
Device financing decreased to $734 million in Q3, less than half the Q2 total, and the $4.9 billion in M&As was a sharp decline versus Q2. Diagnostics fundraising, at $399 million, showed a 31% drop from Q2, and Merck KGAA’s $16.7 billion buy of Sigma-Aldrich made up 96% of the Q3 M&A activity.